The vision to change the world 

Lifechanging therapy by global leaders in ophthalmology 

Eyerising International is an Australian MedTech company developing life-impacting eye-health therapy to slow the progression of myopia. We are led by a team of world-renowned ophthalmology academics, researchers and a board with a proven track record in MedTech innovation, implementation, and clinical facilitation.

Patented childhood myopia control therapy

Eyerising International’s Myopia Management Repeated Low-Level RedLight (RLRL) therapy was conceived and developed by ERI’s Chief Medical Officer, Professor Mingguang He, a global leader in myopia control and the development of artificial intelligence systems in ophthalmology. This innovation in childhood myopia control meets the quality, safety, and efficacy standards required by medical regulators in over 30 countries across Europe and Australasia.

Jason Sun

Founder, MD

Globally connected MedTech entrepreneur and healthcare / business executive  20+ years of health experience at a senior level Secured >10 regulatory approvals  Raised >$20m AUD with successful exits Co-founder of two MedTech companies.

Michael Woods

Executive Director

Specialist investor and adviser in medical technology commercialization  Non-executive director of Optain Health Inc  Prior senior roles at Macquarie Group, Equis Funds Group.

Manny Pascual

Head of Commercial

Over 20 years of experience in the medical device industry Previous Marketing Director for CooperVision Asia Pacific Previous success in medical device company business expansion and acceleration.

David Holland

Business Development Manager (Australasia)

Federico Roma

CTO Accomplished technology leader

Dr. Yuri Aung

Clinical Affairs and RAQA Manager

Dr. Lisa Zhuoting Zhu

Director of Clinical Development

Availability

Currently seeking distribution partners globally.